Results 111 to 120 of about 6,835,633 (348)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Hedgehog Signalling in Androgen Independent Prostate Cancer [PDF]

, 2008
Objectives: Androgen-deprivation therapy effectively shrinks hormone-naïve prostate cancer, both in the prostate and at sites of distant metastasis.
Bisson, Isabelle, Ktori, Elena, McFaul, Siobhan, Oliver, R. Tim D, Price, Anna M., Prowse, David M., Purkis, Patricia E., Shaw, Greg   +7 more
core   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Menopausal hormone therapy: oncological risks

Лечащий Врач, 2021
The article presents generalized data on cancer risks during menopausal hormone therapy (MHT). It is shown that, in proper MHT prescription, it is possible to achieve targeted treatment outcomes without increasing cancer risk.
I. V. Madyanov, T. S. Madyanova
doaj  

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Decision aids for people facing health treatment or screening decisions (Review) [PDF]

, 2009
Background Decision aids prepare people to participate in ’close call’ decisions that involve weighing benefits, harms, and scientific uncertainty. Objectives To conduct a systematic review of randomised controlled trials (RCTs) evaluating the efficacy ...
Adab, Armstrong, Auvinen, Auvinen, Barry, Bastian, Bekker, Bekker, Bekker, Bernstein, Briss, Brown, Brundage, Chadwick, Charles, Chewning, Clancy, Colella, Coulter, Crang-Svalenius, Davison, Davison, Deber, Deber, Degner, Deschamps, Deyo, Dodin, Dolan, Dunn, Elwyn, Emmett, Ende, Entwistle, Flood, Frosch, Frosch, Gafni, Gattellari, Gattellari, Godlee, Goel, Graham, Gravel, Green, Green, Green, Green, Greenfield, Gruppen, Gruppen, Hays, Healton, Herrera, Hewison, Hickish, Hochlehnert, Holloway, Holmes-Rovner, Hunt, Hunter, Hunter, Jadad, Johnson, Jorm, Kennedy, LaCroix, Lalonde, Laupacis, Lazcano Ponce, Legare, Lerman, Leung, Lewis, Llewellyn-Thomas, Maisels, Makoul, Man-Son-Hing, Manns, Markham, Martin, Maslin, Maslin, Mazur, McAlister, McBride, McGinley, McInerney-Leo, Michie, Miller, Molenaar, Molenaar, Montgomery, Morgan, Mulley, Mulley, Murray, Murray, Myers, Myers, Nagle, Newton, O'Cathain, O'Connor, O'Connor, O'Connor, O'Connor, O'Connor, O'Connor, O'Connor, O'Connor, O'Connor, O'Connor, O'Connor, O'Connor, O'Connor, O'Connor, Oakley, Partin, Pearson, Peele, Phelan, Phillips, Pignone, Proctor, Radloff, Ratliff, Rimer, Rimer, Roland, Roosmalen, Roosmalen, Rostom, Rothert, Rothert, Rovner, Ruland, Ryser, Schapira, Schwartz, Sepucha, Sheridan, Shorten, Sorenson, Spielberger, Stacey, Steiner, Stewart, Street, Street, Tabak, Thomson, Thornton, Valdez, Volk, Volk, Vuorma, Vuorma, Wagner, Wallston, Wang, Whelan, Whelan, Whitney, Willemsen, Wolf, Wolf, Wolf, Wong, Wroe, Zapka   +170 more
core   +3 more sources

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Different effects of oral and transdermal hormone replacement therapies on Factor IX, APC resistance, t-PA, PAI and C- reactive protein - a cross-sectional population survey [PDF]

, 2001
The effects of hormone replacement therapy (HRT) on thrombosis risk, thrombotic variables, and the inflammatory marker C- reactive protein (CRP) may vary by route of administration (oral versus transdermal).
Lowe, G.D.O., McConnachie, A., O'Reilly, D.S., Rumley, A., Upton, M.N., Watt, G.C.M.   +5 more
core  

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor [PDF]

, 2005
Prostate cancer is the second most common male malignancy in the western world an increasing incidence in an ageing population. Treatment of advanced prostate cancer relies on androgen deprivation.
Bakin RE, Buchanan G, Chang C, Davies MA, Malik SN, Marcelli M, Taplin ME, Thakkar H   +7 more
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source